Limits...
Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH

Related in: MedlinePlus

Effect of Icariin on TGF-β IR.At age of 5 months, increased TGF-β1 IR was observed in cortex of transgenic mice. A and B: In comparison of serial section of Aβ staining (A), TGF-β1 IR (B) had generally less intensity and smaller IR area, and was mainly located at or around Aβ plaques, but could be barely seen on glial cells or neurons. C and D: Much less intensity and smaller TGF-β1 IR area were seen in the Icariin treated group (D), compared to the control group (C). E and F: Statistical evaluation showed significant reductions in counts of TGF-β1+ plaques and area of TGF-β1 IR.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g006: Effect of Icariin on TGF-β IR.At age of 5 months, increased TGF-β1 IR was observed in cortex of transgenic mice. A and B: In comparison of serial section of Aβ staining (A), TGF-β1 IR (B) had generally less intensity and smaller IR area, and was mainly located at or around Aβ plaques, but could be barely seen on glial cells or neurons. C and D: Much less intensity and smaller TGF-β1 IR area were seen in the Icariin treated group (D), compared to the control group (C). E and F: Statistical evaluation showed significant reductions in counts of TGF-β1+ plaques and area of TGF-β1 IR.

Mentions: Until 3 months of age, TGF-β1 IR could not be seen in cortex or hippocampus of transgenic and naïve mice (data not shown). At age of 5 months, increased TGF-β1 IR was observed and mainly located on or around Aβ plaques, but could barely be seen on glial cells or neurons, according to the results of double staining and in comparison with serial sections of Aβ staining (Figure 6A and B). TGF-β1 IR therefore presented an Aβ plaque-like distribution pattern, but with much less intensity and smaller IR area compared to Aβ staining, as presented in the figure 6 (Figure 6A and B). TGF-β1 IR was more concentrated at the range of plaques and diffused branches, less in the center of plaques.


Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Effect of Icariin on TGF-β IR.At age of 5 months, increased TGF-β1 IR was observed in cortex of transgenic mice. A and B: In comparison of serial section of Aβ staining (A), TGF-β1 IR (B) had generally less intensity and smaller IR area, and was mainly located at or around Aβ plaques, but could be barely seen on glial cells or neurons. C and D: Much less intensity and smaller TGF-β1 IR area were seen in the Icariin treated group (D), compared to the control group (C). E and F: Statistical evaluation showed significant reductions in counts of TGF-β1+ plaques and area of TGF-β1 IR.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g006: Effect of Icariin on TGF-β IR.At age of 5 months, increased TGF-β1 IR was observed in cortex of transgenic mice. A and B: In comparison of serial section of Aβ staining (A), TGF-β1 IR (B) had generally less intensity and smaller IR area, and was mainly located at or around Aβ plaques, but could be barely seen on glial cells or neurons. C and D: Much less intensity and smaller TGF-β1 IR area were seen in the Icariin treated group (D), compared to the control group (C). E and F: Statistical evaluation showed significant reductions in counts of TGF-β1+ plaques and area of TGF-β1 IR.
Mentions: Until 3 months of age, TGF-β1 IR could not be seen in cortex or hippocampus of transgenic and naïve mice (data not shown). At age of 5 months, increased TGF-β1 IR was observed and mainly located on or around Aβ plaques, but could barely be seen on glial cells or neurons, according to the results of double staining and in comparison with serial sections of Aβ staining (Figure 6A and B). TGF-β1 IR therefore presented an Aβ plaque-like distribution pattern, but with much less intensity and smaller IR area compared to Aβ staining, as presented in the figure 6 (Figure 6A and B). TGF-β1 IR was more concentrated at the range of plaques and diffused branches, less in the center of plaques.

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH
Related in: MedlinePlus